Cordlife GroupCLIFF 33 Days Payable is 240.14 as of Mar. 2026, which is 235% above its 10-year median of 71.68. GuruFocus rates CLIFF with a GF Score™ of 33/100 and a GF Value™ of $0.08 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 191 Medical Diagnostics & Research companies, Cordlife Group ranks better than 85.34% on this metric.
The historical rank and industry rank for Cordlife Group's Days Payable or its related term are showing as below:
CLIFF'
s Days Payable Range Over the Past 10 Years
Min: 39.16 Med: 71.68 Max: 292.08
Current: 292.08
During the past 13 years, Cordlife Group's highest Days Payable was 292.08. The lowest was 39.16. And the median was 71.68.
CLIFF's Days Payable is ranked better than 85.34% of 191
companies
in the Medical Diagnostics & Research industry
Industry Median: 68.87
vs CLIFF: 292.08
Cordlife Group's Days Payable
increased
from Mar. 2025 (82.02) to Mar. 2026 (240.14).
It may suggest that Cordlife Groupdelayed paying its suppliers.
Cordlife Group Days Payable Related Terms
Cordlife Group Days Payable Historical Data
* Premium members only.
The historical data trend for Cordlife Group's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Cordlife Group's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cordlife Group Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cordlife Group's Days Payable distribution charts can be found below:
* The bar in red indicates where Cordlife Group's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Cordlife Group's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cordlife Group (CLIFF) has a Days Payable of 240.14 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cordlife Group and its competitors. This is 235% above median its historical median of 71.68. Over the past decade, Cordlife Group's Days Payable has ranged from 39.16 to 292.08. According to the industry distribution chart, Cordlife Group ranks #28 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 14.7%.
Is Cordlife Group's Days Payable too high?
Cordlife Group's current Days Payable of 240.14 is 235% above median its 10-year median of 71.68. Over the past 10 years, this metric has ranged from a low of 39.16 to a high of 292.08. The Medical Diagnostics & Research industry median Days Payable is 68.87. Cordlife Group's value of 240.14 is 248.7% above this industry median. Based on the distribution chart, Cordlife Group ranks #28 out of 191 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Cordlife Group has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cordlife Group's Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cordlife Group ranks #28 out of 191 companies for Days Payable. This places Cordlife Group in the top 15% of its industry — outperforming the majority of peers. The industry median Days Payable is 68.87. Cordlife Group's value of 240.14 is 248.7% above this benchmark. Historically, Cordlife Group's own Days Payable has ranged from 39.16 to 292.08 over the past decade. While the company's 10-year median is 71.68 vs. the industry median of 68.87, Cordlife Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 68.87, based on 191 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cordlife Group's current Days Payable of 240.14 is 248.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cordlife Group and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 68.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cordlife Group's current Days Payable is 240.14, which is 235% above median its own 10-year median of 71.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cordlife Group stock overvalued right now?
Based on GuruFocus' analysis, Cordlife Group (CLIFF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.08, compared to a current price of $0.15 — trading 88.1% above its estimated fair value. The current Days Payable is 240.14, which is 235% above median its 10-year median of 71.68 and 248.7% above the Medical Diagnostics & Research industry median of 68.87. Cordlife Group's overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Cordlife Group (CLIFF), the current Days Payable is 240.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cordlife Group (CLIFF) Overvalued in 2026?
Based on GuruFocus' analysis, Cordlife Group stock appears to be overvalued.
The current stock price of $0.15 is trading 88.1% above its estimated GF Value™ of $0.08.
GuruFocus considers Cordlife Group to be Significantly Overvalued.
Key valuation signals for CLIFF:
Days Payable: 240.14 (235% above median its 10-year median of 71.68)
GF Value™: $0.08 vs. price of $0.15 (88.1% above fair value)
Industry Position: 248.7% above the Medical Diagnostics & Research median (#28 of 191)
No single metric tells the full story. See the CLIFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cordlife Group Ltd is a consumer healthcare company dedicated to safeguarding the well-being of mother and child. Along with its subsidiaries, the company is engaged in the provision of diagnostics and cord blood banking services, which involve the processing and storage of cord blood stem cells. The group has two reportable segments as follows: the Banking segment, which derives maximum revenue, comprises the collection, processing, and banking of biological materials; and the Diagnostics segment, which comprises diagnostics testing services. Geographically, the group generates maximum revenue from Hong Kong, and the rest from the Philippines, India, Malaysia, Singapore, and other regions.
33GF Score
Get the complete analysis for CLIFF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLIFF has been successfully added to your 
